oncbrain — oncology meeting digest

Multicenter TMT Bladder Preservation Analysis (n=369)

Tue, 19 May 2026 00:00:00 GMT

[Confirmatory] CLR 63.7% in 369 MIBC pts on definitive TMT; 5-FU-based CRT and better image guidance predicted higher complete local response. Eligible: Muscle-invasive bladder, cT2-T4aN0M0, median age 76

Single-fraction SABR for primary NSCLC and lung oligomets (pooled, n=1687)

Tue, 19 May 2026 00:00:00 GMT

[Early signal] 2-yr local control 90-93% and G3+ AEs 2-3% across 1687 pts (1200 primary NSCLC, 487 oligomets) treated with single-fraction SABR. Eligible: Primary NSCLC or pulmonary oligometastases, SABR candidates

AUA 2026: ePLND / PSMA PET staging round-up

Tue, 19 May 2026 00:00:00 GMT

PSMA PET NPV ~96% may safely omit ePLND in intermediate-risk pts; 47.7% of nodal mets fall outside the ePLND template.

OPERA Trial (5-year)

Mon, 18 May 2026 00:00:00 GMT

[Caveats dominate] 76% achieved a good clinical response at W14 (DRE+rectoscopy); nCR matched cCR for 5yr organ preservation (77% vs 81%), enabling early W&W selection. Eligible: Rectal cancer, post-neoadjuvant therapy

HEAT Trial

Mon, 18 May 2026 00:00:00 GMT

[Early signal] AHRT 5fx non-inferior to EHRT 26fx for biochemical failure, 7% vs 7.4% (P_NI=0.007) at 4.25y; less acute GI toxicity. Eligible: Localized low- to intermediate-risk prostate cancer, IPSS <12

PEACE 2

Mon, 18 May 2026 00:00:00 GMT

[Challenges SOC] Pelvic nodal RT missed 1° endpoint: 7yr cPFS 67.1% vs 62.9% prostate-only, HR 0.81 (0.63-1.03) p=0.088; no MFS/PCSS/OS gain. Eligible: cN0 very-high-risk localized prostate (Gleason≥8, T3-4, or PSA≥20)

TORPEdO

Mon, 18 May 2026 00:00:00 GMT

[Confirmatory] UW-QoL physical composite similar IMPT vs IMRT at 3/12/24mo in OPSCC; no proton QoL-toxicity benefit (no effect size reported in source). Eligible: Oropharyngeal SCC requiring bilateral-neck concurrent chemoradiotherapy

Proton versus photon therapy for oropharyngeal cancer

Mon, 18 May 2026 00:00:00 GMT

Lancet correspondence on proton vs photon for oropharynx; no effect sizes reported in source (title/citation only).

INRT-AIR & DARTBOARD pooled analysis

Mon, 18 May 2026 00:00:00 GMT

[Early signal] 5-yr solitary elective nodal recurrence 0% with ENI omission across 117 pts; 5-yr OS 87%, PFS 74%. Eligible: Oropharynx/larynx/hypopharynx HNSCC, stage I-IVB, excl T1-2N0 larynx

Multinational HCC EBRT IPD Cohort

Mon, 18 May 2026 00:00:00 GMT

[Confirmatory] Median OS 6.8y BCLC-0 and 4.6y BCLC-A across 4,913 EBRT-treated HCC pts, comparable to resection/ablation. Eligible: Very early / early-stage HCC (BCLC-0 to A), Child-Pugh A predominant

EXTEND Trial

Mon, 18 May 2026 00:00:00 GMT

[Confirmatory] MDT+SOC improved PFS across all baskets, HR 0.54 (0.41-0.72), p<0.001; RT delivered 98% of MDT. Eligible: Oligometastatic solid tumors, 1-5 mets, on standard systemic therapy

FASTRACK II

Mon, 18 May 2026 00:00:00 GMT

[Early signal] 100% freedom from local progression at 36, 60, and 84 months after single-fraction 26 Gy or 42 Gy/3fx SABR in inoperable primary RCC. Eligible: Primary RCC ≤10 cm, medically inoperable or declined surgery, N0-N1

NRG/RTOG 1005

Mon, 18 May 2026 00:00:00 GMT

[Confirmatory] 7-yr IBR 2.6% vs 2.2%, HR 1.31 (90% CI 0.84-2.04): concurrent boost noninferior to sequential, cutting WBI+boost to 15 fractions. Eligible: High-risk early breast cancer post-lumpectomy, receiving WBI plus cavity boost

POP-RT vs PEACE-2

Sun, 17 May 2026 00:00:00 GMT

WPRT bFFS HR 0.50 in POP-RT vs bPFS HR 0.97 in PEACE-2; pelvic nodal RT benefit vanishes with 3yr ADT and higher prostate dose.

PRIME

Sun, 17 May 2026 00:00:00 GMT

[Early signal] Interim data: 36.25 Gy/5 fx SBRT with whole-pelvis RT and 2y ADT shows no inferiority signal vs 68 Gy/25 fx; BFFS immature. Eligible: High-risk, very high-risk and/or node-positive non-metastatic prostate, 2y ADT

PIVOTALboost

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] Late 2yr G2+ bowel 8.2% / 8.7% / 6.5% and bladder 19.5% / 24.1% / 16.5% across prostate, +boost, +pelvic nodes arms. Eligible: High-risk localised prostate, 20-fraction IMRT candidates

PACE-NODES

Sun, 17 May 2026 00:00:00 GMT

[Early signal] Grade ≥2 GI toxicity 28% vs 21% with added pelvic nodal SBRT over 12wk; GU unchanged, symptoms resolved by 12wk. Eligible: High-risk localised prostate (T3a-T4, Gleason 8-10, or PSA>20), planned 12-36mo…

PEACE-2

Sun, 17 May 2026 00:00:00 GMT

[Challenges SOC] 7yr cPFS 67.1% pelvic vs 62.9% prostate-only RT, HR 0.81 (0.63-1.03), p=0.088: primary endpoint not met. Eligible: Very high-risk localized N0M0 prostate ca (≥2 of GS≥8, T3-T4, PSA≥20)

RADIOSA (MFS post-hoc)

Sun, 17 May 2026 00:00:00 GMT

[Caveats dominate] Post-hoc MFS 16.6mo vs not reached, HR 0.39 favoring SBRT + 6mo ADT over SBRT alone in oligorecurrent prostate. Eligible: Oligorecurrent prostate cancer eligible for metastasis-directed SBRT

OLIGOMA

Sun, 17 May 2026 00:00:00 GMT

[Early signal] mPFS 35.8 vs 20.4mo, HR 0.48 (0.25-0.91), p=0.021 for MDT to all lesions in oligometastatic breast, QoL non-inferior. Eligible: Oligometastatic breast, ≤5 lesions, any line, mostly ER+/HER2- first line

APBI-IMRT Florence

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] 15yr IBTR 7.7% APBI vs 4.2% WBI, HR 1.57 (0.82-3.04) p=0.17; excess is new primaries, not true local relapse. Eligible: Post-BCS early breast cancer, pT <25mm, margins ≥5mm, age >40

DBCG RT Natural

Sun, 17 May 2026 00:00:00 GMT

[Challenges SOC] 5yr invasive LR 1.5% with PBI vs 9.8% randomised no-PBI vs 8.2% self-selected no-PBI; RT+ET arm had zero events. Eligible: ≥60yr, pT1N0 unifocal non-lobular ER≥10% HER2-normal grade 1-2, margin ≥2mm

EORTC IM-MS (22922/10925)

Sun, 17 May 2026 00:00:00 GMT

[Challenges SOC] 20yr OS 61.0% vs 61.8%, HR 1.00 (0.90-1.10), P=0.967: early 15yr survival signal gone, BCM benefit offset by non-BCM deaths. Eligible: Stage I-III breast cancer, incl. pN0, considering IM + medial supraclavicular RT

IMPORT HIGH

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] 10yr IBTR 3.5% vs 3.7% vs 5.5% across 40+16Gy, 48Gy SIB, 53Gy SIB; further escalation adds nothing. Eligible: Invasive early breast pT1-3 pN0-pN3a M0 post-BCS requiring tumour bed boost

HypoG-01

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] 118 first events at 4.8y median f/u; LRR infrequent and mostly in-volume, patterns comparable between 40Gy/15fx and 50Gy/25fx. Eligible: Breast cancer receiving adjuvant RT + tumour-bed boost per HypoG-01 eligibility

DBCG HYPO

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] 10-yr grade 2-3 breast induration 19.5% with 40Gy/15fx vs 24.7% with 50Gy/25fx, HR 0.76, p=0.005; no recurrence or survival cost. Eligible: Node-negative early breast cancer or DCIS after breast-conserving surgery

Tumour bed boost after BCS + WBRT

Sun, 17 May 2026 00:00:00 GMT

[Caveats dominate] 10-yr IBTR 1.2% no-boost vs 1.2% boost in 0-2 risk factors; boost omission viable in modern systemic era. Eligible: Post-BCS invasive breast cancer treated with WBRT, Dutch cohort 2012-2016

RCC SBRT local control

Sun, 17 May 2026 00:00:00 GMT

[Unclear] 100% local control at 5 years for primary RCC treated with SBRT, per a conference tweet with no denominator.

OligoCare

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] Real-world SABR local in-field progression 5.0% at 1yr, 11.4% at 3yrs across 2447 pts / 3533 lesions; CRC worst. Eligible: Oligometastatic solid tumors treated with SABR; prostate/NSCLC/CRC/breast…

EXTEND

Sun, 17 May 2026 00:00:00 GMT

[Early signal] Primary aggregated analysis across all tumor-histology baskets now published in JCO; no effect sizes reported in source tweet. Eligible: Oligometastatic solid tumors, mixed histology, on standard-of-care systemic…

DIREKHT

Sun, 17 May 2026 00:00:00 GMT

[Unclear] Contralateral neck sparing and 56 Gy primary CTV de-escalation in selected post-op HNSCC; no effect sizes reported in source tweets. Eligible: Resected HNSCC, post-operative RT candidates